The lawsuit, filed by the Rosen Law Firm, centers on claims that Beta Bionics provided false and misleading information about the safety of its automated insulin pump. According to the complaint, while the company downplayed regulatory concerns as benign, the FDA had documented thousands of malfunctions involving the iLet device. These malfunctions allegedly resulted in patients receiving dangerously high doses of insulin, triggering life-threatening hypoglycemic events that required emergency medical intervention.

The litigation asserts that the company failed to implement necessary corrective measures despite mounting safety reports. Investors who purchased stock during the defined class period are eligible to participate in the ongoing litigation, which operates on a contingency fee basis. As the case proceeds, interested parties may choose to serve as a lead plaintiff to help direct the litigation or remain as absent class members. No class has been certified, and investors retain the right to select their own legal counsel.